ZMYND11, also known as BS69, was originally defined as a transcriptional co-repressor and putative tumor suppressor, due to its capability to directly interact with and inhibit the transactivation activities of a set of viral and cellular oncoproteins, which include Adenovirus Early Region 1A (E1A), Epstein–Barr virus nuclear antigen 2 (EBNA2) and MYB13–15. The gene discussed is ZMYND11; the disease is neoplasm.